ARA-290
2 RCTsWell researched
| Trialled in humans for neuropathic pain | supported |
| Improved small-fibre neuropathy measures in sarcoidosis | partially true |
| A general-purpose healing peptide | overreach |
Goal matrix
Healing & repair
Every compound we track for this goal.
1 Well researched2 Emerging3 Limited evidence
TB-500
2 RCTsEmerging
| Improves soft-tissue recovery | animal data only |
| Banned in competitive sport | supported |
BPC-157
0 RCTsEmerging
| Accelerates tendon and ligament healing | animal data only |
| Heals the gut lining | animal data only |
| Reverses existing injury in humans | overreach |
| Well tolerated in reported use | partially true |
GLOW blend
—Limited evidence
| Combines three compounds with individual research behind them | partially true |
| The blend itself has been clinically tested | overreach |
KLOW blend
—Limited evidence
| Adds an anti-inflammatory component to GLOW | partially true |
| The four-way combination is studied as one product | overreach |
BPC-157 / TB-500 blend
—Limited evidence
| The two mechanisms complement each other | preclinical only |
| Backed by human trials as a combination | overreach |
| Both components prohibited in competitive sport | supported |
→